Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes

Keyphrases

• Type 2 Diabetic Patients 100%
• Blood Pressure Lowering 100%
• Microvascular Events 100%
• First Year 66%
• All-cause Mortality 66%
• Placebo Groups 66%
• Active Groups 66%
• Macrovascular Events 66%
• Placebo 33%
• Hazard Ratio 33%
• Cox Proportional Hazards Model 33%
• Diabetes Disease 33%
• Vascular Disease 33%
• Multivariable 33%
• Clinical High Risk 33%
• Control Evaluation 33%
• Time-dependent Covariates 33%
• Residual Effect 33%
• Diamicron 33%
• Active Treatment 33%
• Treatment Discontinuation 33%
• Glucose Control 33%
• Fixed Combination 33%
• Indapamide 33%
• Perindopril 33%
• Risk Markers 33%
• Event Rate 33%
• Evaluation Trial 33%
• Macro-event 33%
• Intensive Glucose Control 33%
• Factorial Randomized Controlled Trial 33%

Medicine and Dentistry

• Blood Pressure 100%
• Placebo 100%
• Patient with Type 2 Diabetes 100%
• All Cause Mortality 66%
• Glucose 66%
• Diabetes 33%
• Clinician 33%
• Randomized Controlled Trial 33%
• Proportional Hazards Model 33%
• Hazard Ratio 33%
• Vascular Disease 33%
• Gliclazide 33%
• Indapamide Plus Perindopril 33%
• Perindopril 33%
• Indapamide 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Maturity Onset Diabetes of the Young 100%
• All Cause Mortality 66%
• Glucose 66%
• Randomized Controlled Trial 33%
• Vascular Disease 33%
• Gliclazide 33%
• Indapamide Plus Perindopril 33%
• Indapamide 33%
• Perindopril 33%